Released Aug 14, 2017, after the close
10-Q filed Aug 14, 2017, 45 days after period end · 0001390478-17-000059
Q2 2017 · 10-Q
Revenue—
Net Income-$5.91M-$5.91M N/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.22-$0.22 N/M vs Q2 2016N/M vs Q1 2017
Operating Income-$4,911,000N/M
Operating Cash Flowderived-$3,049,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2017 | Q2 2016 | Q2 2013 | Q2 2012 |
|---|---|---|---|---|
| Revenue | — | — | $3.38M | $3.38M |
| Net Income | -$5.91M | $5.39M | $5.39M | -$15.66M |
| EPS Diluted | -$0.22 | $0.58 | -$0.11 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR